Thomas Michalsen, DO
General Practice · Kirkland, ILNPI 1114947876
Payments from drug & device makers
Across 91 payments — averaging $31.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$790
- Lilly USA, LLC$270
- Boehringer Ingelheim$257
- Acadia Pharmaceuticals Inc$250
- Sunovion Pharmaceuticals Inc.$178
- Bayer$165
- plus $940 from 18 others
What the payments were for
- Food & beverage$2,83599%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $790 |
| Lilly USA, LLC | 13 | $270 |
| Boehringer Ingelheim | 17 | $257 |
| Acadia Pharmaceuticals Inc | 2 | $250 |
| Sunovion Pharmaceuticals Inc. | 14 | $178 |
| Bayer | 4 | $165 |
| Johnson & Johnson | 3 | $146 |
| Amarin Pharma, Inc. | 2 | $129 |
| Novartis | 2 | $119 |
| Merck | 1 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Sanofi | 1 | $44 |
| Cipher Pharmaceuticals US LLC | 1 | $43 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Genentech USA, Inc. | 3 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Novo Nordisk | 2 | $32 |
| AbbVie | 2 | $28 |
| Pfizer | 2 | $28 |
| Nevro Corp. | 1 | $23 |
| Smith+Nephew | 1 | $23 |
| GSK | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,850 in reported general payments places this provider in the 95th percentile of 3,816 general practice providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 320 | $383,318 |
| EliquisApixaban | 1,087 | $322,196 |
| XareltoRivaroxaban | 820 | $273,913 |
| IngrezzaValbenazine Tosylate | 40 | $223,594 |
| TrulicityDulaglutide | 217 | $164,354 |
| JardianceEmpagliflozin | 402 | $159,419 |
| AptiomEslicarbazepine Acetate | 240 | $149,533 |
| OzempicSemaglutide | 126 | $144,218 |
| RebifInterferon Beta-1a/Albumin | 11 | $121,416 |
| FarxigaDapagliflozin Propanediol | 129 | $115,535 |
| HumiraAdalimumab | 12 | $90,371 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $80,636 |
| GemtesaVibegron | 179 | $58,770 |
| Breo ElliptaFluticasone/Vilanterol | 111 | $53,735 |
| GlatopaGlatiramer Acetate | 11 | $52,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $270 | $547,672537 claims |
| PfizerEliquis | $28 | $322,1961,087 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $146 | $295,060831 claims |
| Boehringer IngelheimJardiance, Glyxambi | $257 | $184,398428 claims |
| AbbVieHumira, Linzess, Creon | $28 | $164,16275 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $20 | $155,116270 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $178 | $149,533240 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $790 | $144,352162 claims |
| Novo NordiskOzempic | $32 | $144,218126 claims |
| Acadia Pharmaceuticals IncNuplazid | $250 | $49,34512 claims |
| MerckJanuvia | $87 | $35,123122 claims |
| NovartisEntresto | $119 | $26,69890 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,816 general practice providers in Illinois.
Other general practice in Kirkland
- Ryan MolisBurr Ridge$13M
- Ronald StumbrisPalos Heights$3.8M
- Lou GrahamChicago$603K
- Kenya ThomasChicago$595K
- Brijesh PatelSchaumburg$547K
- Alan BoghosianChicago$349K
- Anthony PonzioElmwood Park$253K
- Dennis HartliebGlenview$160K
- Miguel NayanWestmont$149K
- Peter HarnoisHinsdale$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.